SomaGenics

SomaGenics is a biotechnology company that focuses on small RNA analysis and therapeutics, specializing in the detection and analysis of microRNAs and other small RNA molecules through advanced PCR technology. Founded in 1997, SomaGenics is headquartered in Santa Cruz, US. The company specializes in small RNA analysis and therapeutics, utilizing its proprietary technology to serve a global clientele. CEO Brian Johnston, who has a history of involvement in biotechnology ventures, leads the company.

SomaGenics specializes in small RNA analysis and therapeutics, primarily focusing on the detection and analysis of microRNAs (miRNAs) and other small RNA molecules through its proprietary PCR technology. This platform is engineered to work effectively with biofluids or total RNA inputs, making it versatile for various applications in molecular biology and diagnostics. One of the company's flagship innovations is the sshRNA® (short interfering RNA), which is designed to achieve high potency and favorable pharmacokinetic properties while minimizing undesirable immune responses commonly associated with RNA interference (RNAi) methods. SomaGenics targets a range of clientele, including research institutions, pharmaceutical companies, and academic laboratories in North America, Europe, and Asia.

The primary end users are researchers and scientists who utilize these technologies for disease research, biomarker discovery, and therapeutic development. SomaGenics generates revenue through the sale of its specialized RNA analysis platforms and therapeutic products, particularly its trademarked sshRNA® offerings. The company engages in transactions primarily through direct business-to-business relationships, providing its technologies and services to research institutions and pharmaceutical companies that seek to develop RNA-based therapeutics. Partnerships and collaborations with clients are structured around project-based agreements or subscriptions, depending on the nature of the research and therapeutic programs.

Pricing structures for these products vary according to the specific services and technologies provided, though details regarding specific costs are not disclosed. The company’s revenue is driven by the demand for advanced small RNA analysis and the therapeutic applications of its proprietary technologies.